id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-265006-m1dmgcd1	Kow, Chia Siang	Do the meta-analyses provide a clean bill of health to the use of renin-angiotensin system inhibitors in COVID-19?	2020-08-08		.txt	text/plain	842	56	47	In fact, we are aware of the publication of few systematic reviews and metaanalyses [2] [3] [4] [5] [6] [7] [8] which included these observational studies with questionable quality to determine the association between renin-angiotensin system (RAS) inhibitors use, including angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), and mortality/severity of COVID-19. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis	./cache/cord-265006-m1dmgcd1.txt	./txt/cord-265006-m1dmgcd1.txt